ArticleClinical and experimental immunology2007
Increased serum high mobility group box-1 level in Churg-Strauss syndrome.
Article in Clinical and experimental immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response.Journal of immunology research · 2015Article
- HMGB1 in health and disease.Molecular aspects of medicine · 2014Review
- High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.European journal of pediatrics · 2014Review
- Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.Clinical and experimental immunology · 2014Review
- Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis.Clinical and experimental immunology · 2013Article
- Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome.Allergy · 2012Article
- HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease.Nature reviews. Rheumatology · 2012Review
- High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus.Arthritis research & therapy · 2011Article
- Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis.Clinical and experimental immunology · 2009Review
- Churg-Strauss syndrome: 2005-2008 update.Current rheumatology reports · 2008Review
- The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation.Modern rheumatology · 2008Review
Corrections and comments
- Retraction · 2008-11-05Falsification/Fabrication of Data · Investigation by Company/Institution · Misconduct by Author · · 3/28/2017
- RetractedRetraction.2008
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Churg-Strauss syndrome (CSS) is a rare form of systemic vasculitis occurring in patients with asthma and hypereosinophilia; however, its mechanisms involved in the severe tissue inflammation with vasculitis are poorly understood. High mobility group box 1 (HMGB1) protein, originally identified as a DNA binding protein, also has potent pro-inflammatory and proangiogenic properties. In this study, we hypothesized that HMGB1 might be associated with CSS, and examined serum HMGB1 levels and compared those of asthma patients and healthy volunteers. We also investigated HMGB1 expression in the lesion, and eosinophil HMGB1 amount in CSS patients. We found that the serum HMGB1 levels in CSS patients were significantly higher than those of asthma patients and healthy volunteers. Eosinophils in the CSS lesion expressed HMGB1 and HMGB1 level in eosinophils from CSS patients was significantly higher than that of asthma patients, while there was no significant difference in HMGB1 levels in peripheral mononuclear cells. The serum HMGB1 level in CSS patients decreased after the steroid therapy, and showed significant positive correlations with several molecules, including soluble interleukin-2 receptor, soluble thrombomodulin, and eosinophil cationic protein in sera. We propose that HMGB1 might contribute to the pathogenesis of CSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.